

## Information for Authors

(Revised January 2017)

### Contents (click on the topic)

[Journal Scope](#) | [Types of Content](#) | [Preparing Your Manuscript](#) | [Editorial Process and Peer Review](#) | [Submission Policies](#) | [Submission Procedure](#) | [Additional Requirements](#) | [Conditions of Acceptance](#) | [Additional Journal Information](#)

*ACS Infectious Diseases* publishes high-quality chemistry and biology research in the field of infectious diseases. Researchers are invited to submit their original work to the journal.

### Journal Scope

#### *Pathogens and Host-Pathogen Interactions*

- Use of structural biology, chemical biology, glycobiology, physical chemistry, nucleic acid chemistry, and biochemistry to elucidate molecular mechanisms of pathogenesis
- Development of tools to dissect mechanisms of pathogenesis

#### *Therapeutics*

- Use of target-, phenotypic-, or computational-based approaches for discovery and development of new agents to treat infectious diseases, with an emphasis on establishing mechanism of action, understanding binding mode and inhibitory mechanism, and/or discussing pathogen-specific challenges to drug development
- Development of new technologies to facilitate characterization, validation, and prioritization of potential drug targets or to assess the physicochemical bases for cellular penetration of anti-infective
- Mechanistic investigations of antimicrobial resistance

#### *Vaccines*

- Discovery and development of synthetic vaccines and small molecule vaccine adjuvants
- Structural, physical, or computational investigations of epitope binding

#### *Diagnostics*

- Development of novel and improved diagnostics using physical, surface, analytical, and nano chemistry techniques
- Use of structural biology, molecular biology, and chemical biology to investigate diagnostics targets

## ***Drug Delivery Systems***

- Use of novel materials and technologies, such as nanotechnologies, for delivery of antimicrobial agents

## **Types of Content**

*ACS Infectious Diseases* publishes original Letters, Articles, Featured Articles, Reviews, and Perspectives that highlight recent developments and further the understanding of infectious diseases. The Editors welcome the submission of manuscripts in the following categories:

**Letters.** Short reports of original research focused on an individual significant finding. Letters are peer-reviewed and begin with an unreferenced abstract of less than 150 words. Abstracts should not contain abbreviations or acronyms unless essential. Letters include unheaded sections for the Introduction and combined Results and Discussion and a headed section for Methods that can also contain subsections. Letters should contain 4–6 display items (figures/tables/schemes) and ~30 references. Letters should include sufficient experimental detail to allow others to reproduce the findings presented. Supporting Information is encouraged. Letters should be less than 4500 words in length, including the abstract, body text, methods, references, and figure/scheme legends. Letters include a graphical Table of Contents entry and a list of up to six keywords.

**Articles.** Concise, yet comprehensive, original research presenting an advance of immediate, broad, and lasting impact. Articles are not intended to be follow-up manuscripts, unless they contain new and extensive information that will advance the understanding of the system or biological process. Articles are peer-reviewed and contain an unreferenced abstract of 250 words or less. Abstracts should not contain abbreviations or acronyms unless essential. A referenced introduction should expand on the background of the work. Articles include the following headed sections (presented in this order): combined Results and Discussion, and Methods. In general, Articles should be less than 6500 words in length and include 7–10 display items (figures/tables/schemes) and ~50 references. Supporting Information may be included. Articles include a graphical Table of Contents entry and a list of up to six keywords.

**Featured Articles.** The Editors may choose to give “Featured Article” status to any Article at the time of acceptance.

**Reviews.** Topical and of general interest to the readership. Reviews are peer-reviewed and contain an unreferenced abstract of 250 words or less. A good Review critically evaluates existing work, provides a logical organization, and makes the material more easily available to those not expert in the area through clear text and figures. Reviews should be greater than 5000 words in length, include 4–8 display items (figures/tables/schemes), and contain ~100 references. Include a graphical Table of Contents entry consisting of a colorful figure that represents the topic of the Review. Authors may choose to divide the Review into sections preceded by headings. Finally, the journal recommends that authors define key words used in the Review and key concepts in a separate paragraph.

**Perspectives.** Submitted by *invitation only*. Perspectives are designed to provide an enlightened appraisal of a field of research in which experts review the “state of the art” for a given topic similar to Reviews. Unlike Reviews, however, authors have editorial freedom to express their views on the strategic directions of the field of research. The Perspective series provides a forum with high visibility

within the pharmaceutical industry, clinical and government research, and academia. Perspectives are peer-reviewed, contain an unreferenced abstract of 250 words or less, and include a graphical Table of Contents. Perspectives should be 3000–6000 words in length, include 3–6 display items (figures/tables/scheme), and contain up to 100 references. Authors may choose to divide the Perspective into sections preceded by headings. Finally, the journal recommends that authors define key words used in the Perspective and key concepts in a separate paragraph.

**Viewpoints.** Submitted by *invitation only*. Viewpoints are general commentaries on topics of immediate interest to the broad readership. Viewpoints are not peer-reviewed. Responses to Viewpoints or other content will be considered.

**Introducing Our Authors.** The journal may also publish features devoted to highlighting the authors included in a particular issue.

**Additions and Corrections.** Additions and Corrections may be used to address important issues or correct errors and omissions of consequence that arise after publication of an article. Additions and Corrections may be requested by the author(s) or initiated by the Editor after discussions with the corresponding author. Readers who detect errors of consequence in the work of others should contact the corresponding author of that work. All Additions and Corrections are subject to approval by the Editor, and minor corrections and additions will not be published. Additions and Corrections from authors should be submitted via the ACS Paragon Plus environment by the corresponding author for publication in the “Addition/Correction” section of the Journal. The corresponding author should obtain approval from all of the article coauthors prior to submitting an Addition and Correction, or provide evidence that such approval has been solicited. The Addition and Correction should include the original article title and author list, citation including DOI, and details of the correction. For proper formatting, see examples in a current issue of the Journal.

**Retractions.** Articles may be retracted for scientific or ethical reasons. Articles that contain seriously flawed or erroneous data such that their findings and conclusions cannot be relied upon may be retracted to correct the scientific record. Retractions may be requested by the article author(s) or by the journal Editor(s), but are ultimately published at the discretion of the Editor. When an article is retracted, a notice of retraction will be published containing information about the original article title, author list, and the reason for the retraction. Retracted articles will be accompanied by the related retraction notice and will be marked as “Retracted”. The originally published article will remain on the web except in extraordinary circumstances (e.g., when deemed legally necessary, or if the availability of the published content poses public health risks). The American Chemical Society follows guidance from the Committee on Publication Ethics (COPE) when considering retractions; for more information see <http://publicationethics.org/>.

## **Preparing Your Manuscript**

Please refer to the Manuscript Submission and Peer Review in ACS Paragon Plus site (<http://paragonplus.acs.org>) for a complete listing of acceptable file formats and tips for working with graphics.

**Text.** Prepare your manuscript as a double-spaced document. Do not include line numbers, these will be automatically added upon submission.

**Tables.** Submit within the body of the manuscript text file.

- Number consecutively using Arabic numbers.
- Include a descriptive heading that, together with the individual column headings, makes the table self-explanatory.
- Give footnotes letter designations and cite them in the table by italic superscript letters. The sequence of letters should proceed by line rather than by column.
- When a reference is cited, insert a lettered footnote in the table and put the reference number in a footnote.
- When columns are used, arrange data efficiently to save space.
- Place crystallographic and NMR data tables last in a series of tables in a manuscript, because they are generally placed in the Methods section.

**Graphics.**

- The preferred submission procedure is to embed graphic files in a Word document. It may help to print the manuscript on a laser printer to ensure all artwork is clear and legible.
- Additional acceptable file formats are TIFF, PDF, EPS (vector artwork), or CDX (ChemDraw file). If submitting individual graphic files in addition to their being embedded in a Word document, ensure the files are named on the basis of graphic function (i.e., Scheme 1, Figure 2, Chart 3), not the scientific name. Labeling of all figure parts should be present, and the parts should be assembled into a single graphic.
  - EPS files: Ensure that all fonts are converted to outlines or embedded in the graphic file. The document settings should be in RGB mode. **NOTE:** *While EPS files are accepted, the vector-based graphics will be rasterized for production.*
- Artwork may be categorized into structure blocks, equations (numbered reactions), schemes, and figures. Within each category, use Arabic numbers to sequentially number artwork.
- All chemical structures should be prepared using ChemDraw and the ACS document settings.
- Schemes may have titles and footnotes.
- Figures must have captions.
- Number structures with boldface Arabic numbers.
- Do not place macromolecular structures on any backgrounds. Choose colors that will allow all features to be clearly visible on white background.
- Submit graphics at the required publication size. Single column graphics are preferred and can be sized up to 240 points wide (3.33 in.). Double column graphics must be sized between 300 and 504 points (4.167 in. and 7 in.). All graphics have a maximum depth of 660 points (9.167 in.) including the caption (please allow 12 pts for each line of caption text).
- TIFF files should be 300 dpi for color and photographic images, 600 dpi for grayscale art (a monochromatic image containing shades of gray), and 1200 dpi for line art.
- For color graphics, format in RGB color scheme.
  - The RGB and resolution requirements are essential for producing high-quality graphics within the published manuscript. Graphics submitted in CMYK or at lower resolutions may be used; however, the colors may not be consistent, and it may not be possible to improve graphics of poor quality.
  - Most graphic programs provide an option for changing the resolution when you are saving the image. Best practice is to save the graphic file at the final resolution and

size using the program used to create the graphic.

- Figures containing photographic material should be in TIFF format.
- Use Arial font for lettering within a graphic.
  - Lettering should be ~6 points, and lines should have ~0.5-point thickness at final published size.
  - Lettering and lines should be of uniform density.
  - Text within a graphic should be initial-capped.
- Panel labels should be bold, lowercase, and in the upper-left corner of the panel
- Do not place a rule around the entire graphic.
- To save space, place legends for graphs within the main body of the graph, whenever possible.
- Graphs containing similar information should be of similar size.
- Name your graphics Figure 1, Figure 2, etc., and cite the graphic in the main manuscript text where it should be located.

## Organization of Paper

**Title.** Titles should clearly and concisely reflect the emphasis and content of the manuscript and be accessible to a broad audience. Titles are of great importance for current awareness and information retrieval and should be carefully constructed for these purposes. **One option that authors may wish to consider is to present a significant outcome in the title. Titles should not contain specialized abbreviations or jargon.** Editors may request author revision of a title at any time prior to publication.

**Author List.** Include all those who have made substantial contributions to the work. To facilitate indexing and retrieval and for unique identification of an author, use first names, initials, and surnames (e.g., John R. Smith) or first initials, second names, and surnames (e.g., J. Robert Smith). At least one author must be designated with an asterisk as the person to whom correspondence should be addressed.

Many Funders and Institutions require that institutional affiliations are identified for all authors listed in the work being submitted. ACS facilitates this requirement by collecting institution information during manuscript submission under Step 2: Authors and Affiliations in ACS Paragon Plus.

**Abstract.** All *Articles, Letters, Reviews, Tutorials, Technical Notes, and Viewpoints* must contain an abstract, which should provide a succinct, informative summation of the most important results and conclusions. Ideally, an abstract should be less than 150 words. References cannot be cited in the abstract. Abbreviations should be used sparingly and spelled out when first used. Abstracts display the same graphic provided for the TOC.

**Keywords.** Authors should provide a list of up to six keywords to be displayed below the abstract of their publication.

**Table of Contents/Abstract Graphic.** Each paper must include a single graphic to be used for the Table of Contents (TOC) and abstract. This graphic should capture the readers' attention and, in conjunction with the manuscript title, give readers a visual impression of the essence of the paper without providing specific details. The best images for these uses are simple and relatively free of text and technical characters and make use of color for visual impact. Tables or spectra are not acceptable as TOC/abstract artwork. At final published size, any text should be ~6 points. These graphics should be ~8 cm (~3.15 in) in width and ~4 cm (~1.57 in) height, and must be ~300 dpi in resolution and in RGB color mode.

**Introduction.** In this unheaded section, the purpose and significance of the research should be clearly stated and placed in the context of earlier work in the area. Historical summaries are seldom warranted. Do not attempt a complete survey of the literature. If a recent article has summarized work on the subject, cite that article without repeating its individual citations. In general, the introductory section should be ~750 words for a letter and ~1000 words for an article.

**Results and Discussion.** Present this section concisely. The first paragraphs should explain the motivation for the work and how it combines the chemistry and biology disciplines. Use tables and figures only if they are essential for comprehension of the data. Do not present the same data in more than one figure or in both a figure and a table. The purpose of the discussion is to interpret the results and relate them to existing knowledge in the field. Manuscripts reporting new 3D structures of small molecules from crystallographic analysis should include a structural figure with probability ellipsoids and a CIF file. Those reporting NMR or X-ray crystal structures of macromolecules must include a table with relevant data collection and refinement statistics. For manuscripts reporting structures derived from electron microscopy experiments, authors must provide one image showing the distribution of particles being analyzed, the percentage of the particles being used in the reconstruction, and a correlation coefficient plot (or equivalent data) to indicate the resolution of the presented structure. Upon request from the Editor, the authors must provide sequence, structure data (including coordinate files and structure), and/or microarray data in a MIAME-compliant format to the Editors and reviewers for the purpose of evaluating the manuscript.

**Methods.** Provide a clear, unambiguous description of materials, methods, and equipment in sufficient detail to permit repetition of the work elsewhere. Describe novel experimental procedures in detail, but refer to published procedures by literature citation of both the original and any published modifications. Manuscripts reporting data from experiments on live animals must include a statement identifying the approving committee and certifying that such experiments were performed in accordance with all national or local guidelines and regulations. Authors must emphasize any unexpected, new, and/or significant hazards or risks associated with the reported work. This information should be in the experimental details section of the full article or communication.

**Supporting Information.** This information is made available to the reviewers during the peer-review process and to readers at the time of publication. The Supporting Information format of this journal can accommodate and make readily available almost any type of supplementary figures or data (e.g., reproductions of spectra, experimental procedures, tabulated data, or expanded discussion of peripheral findings). Supporting Information must be submitted at the same time as the manuscript and uploaded separately to the ACS Paragon Plus Environment. A list of acceptable file types is available on the web <http://paragonplus.acs.org>

If the manuscript is accompanied by any supporting information files for publication, a brief description of each file is required. The paragraph and descriptions should be placed at the end of the manuscript before the list of references. All Supporting Information available as PDF files should be contained in one PDF file and likewise for Excel, etc. files. A paragraph noting the availability of Supporting Information should be placed at the end of the text before the reference listing:

**Supporting Information.** Brief descriptions in nonsentence format listing the contents of the material supplied as Supporting Information.

**Abbreviations.** If you use abbreviations extensively throughout the manuscript, please add this section to spell these out.

**Author Information.** Please provide your current address in this section. *ACS Infectious Diseases* also recommends that individual contributions of authors be listed under a separate subheading entitled "Author Contribution". Please also list "Conflict of Interest" (if any) in another additional subsection.

**Acknowledgment.** Include financial support, technical assistance, advice from colleagues, gifts, etc.

**References.** Compile all references together in a list at the end of the manuscript text. Many of them will have links to other web resources, such as the corresponding abstracts in *Chemical Abstracts* and the full text on publisher websites. Because of this electronic linking, and because the references are not checked in detail by Editors or reviewers, it is crucial that authors verify their accuracy. Avoid unnecessarily long lists of references. However, authors must reference all previous publications in which portions of the present work have appeared. Avoid long references; place additional data and peripheral discussion in the Supporting Information rather than in references. Supplementary references may be placed in Supporting Information. Literature references must be numbered with Arabic numerals in the order of their first citation in the text and the corresponding numbers inserted at the appropriate locations in the text. All journal references should include the Digital Object Identifier (DOI) unique to the citation. Please use the following reference styles (which in EndNote is the *Biochemistry* style).

*For journals:*

1. Moreau, P., Anizon, F., Sancelme, M., Prudhomme, M., Bailly, C., Severe, D., Riou, J.-F., Fabbro, D., Meyer, T., and Aubertin, A.-M. (1999) Syntheses and biological activities of rebeccamycin analogues. Introduction of a halogenoacetyl substituent. *J. Med. Chem.* 42, 584–592. DOI: 10.1021/sb500xxx.

*For journal articles published online ahead of print or online only, the DOI should be used:*

2. Liu, C., and Yang, S. (2009) Synthesis of angstrom-scale anatase titania atomic wires. *ACS Nano* Epub Mar 23, 2009. DOI: 10.1021/nn900157r.

*For books:*

3. Fierke, C. A., and Hammes, G. G. (1996) Transient kinetic approaches to enzyme mechanisms. In *Contemporary Enzyme Kinetics and Mechanism* (Purich, D., Ed.), 2nd ed., pp 1–35, Academic Press, New York.

Titles of journals are abbreviated according to *Chemical Abstracts Service Source Index* (CASSI, <http://cassi.cas.org/search.jsp>). Manuscripts accepted for publication are cited as “in press”; the DOI should be given if the paper is published online. Cite manuscripts that are in preparation or have been submitted but not yet accepted as unpublished experiments or personal communications.

**Web-Enhanced Objects Such as Movies.** *ACS Infectious Diseases* encourages the use of multimedia attachments such as animations and movies. These objects should complement a reader’s understanding of the research being reported. For acceptable file formats and specifications please refer to the web page on Specifications for Web Enhanced Objects (<http://pubs.acs.org/page/4authors/submission/weo.html>).

**ACS Math Style.** Authors including math, display or in-text, in their manuscripts are encouraged to consult the [ACS Guidelines for Presenting Mathematical Information](#). This style sheet provides brief discussion of formatting related to the presentation of mathematical formulas, complete with examples of ACS style and layout. This document was developed to help authors anticipate how mathematical expressions will be formatted in the published version of the paper.

**Preparing and Submitting Manuscripts Using TeX/LaTeX.** Authors who submit manuscripts composed in TeX/LaTeX should submit a PDF file of the manuscript along with the native TeX/LaTeX manuscript package as a ZIP Archive. Use of the freely available **achemso style package** to help prepare your submission is strongly encouraged. The **achemso** package provides the official macros (achemso.cls) and BibTeX styles (achemso.bst and biochem.bst) for submission to ACS journals. The package and instructions are available from [CTAN, the Comprehensive TeX Archive Network](#). For complete information on submitting TeX/LaTeX files, see [Preparing and Submitting Manuscripts Using TeX/LaTeX](#).

**Writing Style and Language Usage.** Chemists, biologists, and engineers with other distinct scientific training read *ACS Infectious Diseases*. Therefore, making all manuscripts accessible to scientists interested in systems and synthetic biology is essential. The Editors will request that authors rewrite any portion of the manuscript if it is not accessible to a broad audience. Clarity and conciseness are critical requirements for publications. Authors should consult *The ACS Style Guide* (<http://pubs.acs.org/page/books/styleguide/index.html>) for guidance on style, word-usage conventions, nomenclature, physical quantity symbols and units, abbreviations, use of italics, and punctuation.

*The ACS Style Guide* also provides information about copyrights and insight on what Editors and reviewers look for in evaluating manuscripts. Spelling and use of periods and commas in numbers should conform to U.S. usage. Any author who is not fully fluent in idiomatic English is urged to obtain assistance with manuscript preparation from a colleague whose native language is English.

**Assistance with Improving Your Manuscript.** Authors may want professional assistance with improving the English, figures, or formatting in their manuscript before submission. ACS ChemWorx Authoring Services can save you time and improve the communication of research in your manuscript. You can learn more about the services offered at <http://es.acschemworx.acs.org>.

**Language Editing and Other Services.** For a list of Language Editing Services a list of free Viewers for Supporting Information, and more information on services and policies of the ACS please refer to the following link: <http://paragonplus.acs.org>.

## **Editorial Process and Peer Review**

Manuscripts are handled expeditiously, and full advantage is taken of web technology in the submission and review of manuscripts.

**The Review Process.** Editors evaluate submitted manuscripts, and only those judged to fall within the scope of the journal and to be of potential interest to our readers are sent to 2 or more reviewers for evaluation. Reviewers can suggest that a paper be published, revised, or rejected. Reviewers will evaluate the originality, technical quality, clarity of presentation, and importance to the field. The Editors evaluate the reviewers' arguments in the context of the scope and aims of the journal and make the final decision on each manuscript.

Please note that editorial decisions are based on many factors. Reviewers' concerns are considered very seriously. In cases when reviewers suggest differing decisions, additional information may be requested from the reviewers, other experts may be consulted, and/or the authors may be asked to clarify questionable sections. Reviewers may be asked to review subsequent versions of the manuscript, especially if new data have been added to the paper, to evaluate whether the authors have addressed the scientific concerns. In such cases, blind copies of all reviewer comments are normally sent to the reviewers. This practice allows the reviewers to obtain a clear understanding of the expectations of the Editors. The Editors will expedite any additional rounds of reviews to ensure timely publication.

**Anonymity.** The ACS strongly disapproves of any attempts by authors to determine the identity of reviewers or to confront potential reviewers. The editorial policy of this journal is to neither confirm nor deny any speculation about the identities of our reviewers. The journal will not release the identity of a reviewer to the authors or to other reviewers.

**Professional Ethics.** All parties—Editors, reviewers, and authors—are expected to adhere to the standards embodied in the American Chemical Society's *Ethical Guidelines to Publication of Chemical Research*, which are available at <http://pubs.acs.org/ethics>. Authors are reminded of their obligation to obtain the consent of all their co-authors before submitting a paper for publication. If any change in authorship is necessary after a paper has been submitted, the corresponding author must mail or fax a signed letter to the Editor confirming that all of the original co-authors have been notified and have agreed to the change. If any author is deleted after a paper has been submitted, the deleted author must mail or fax a signed letter to the Editor confirming that the author has agreed to the change.

In publishing only original research, ACS is committed to deterring plagiarism, including self-plagiarism. ACS Publications uses CrossCheck's iThenticate software to screen submitted manuscripts for similarity to published material. Note that your manuscript may be screened during the submission process. Further information about plagiarism can be found in Part B of the [Ethical Guidelines to Publication of Chemical Research](#).

## Submission Policies

**Conflict of Interest Disclosure.** A statement describing any financial conflicts of interest or lack thereof is published with each manuscript. This statement, provided separately from the manuscript during the submission process, should describe all potential sources of bias, including affiliations, funding sources, and financial or management relationships, that may constitute conflicts of interest (please see the [Ethical Guidelines to Publication of Chemical Research](#)). The corresponding author must provide a statement on behalf of all authors of a manuscript. If no conflict of interest is declared during the submission process, the following statement will be published in the manuscript: “The authors declare no competing financial interest.”

**Author List.** During manuscript submission, the submitting author must provide contact information (full name, e-mail address, institutional affiliation, and mailing address) for each of the co-authors. Because all of the author names are automatically imported into the electronic Journal Publishing Agreement, the names must be entered into ACS Paragon Plus in the same sequence as they appear on the first page of the manuscript. (Note that co-authors are not required to register in ACS Paragon Plus.) The author who submits the manuscript for publication accepts the responsibility of notifying all co-authors that the manuscript is being submitted. Deletion of an author after the manuscript has been submitted requires a confirming letter to the Editor-in-Chief from the author whose name is being deleted. For more information on ethical responsibilities of authors, see the [Ethical Guidelines to Publication of Chemical Research](#).

**Costs.** *ACS Infectious Diseases* does not impose any submission or publication fees.

**Database Deposition. Sequence Data.** Papers reporting protein or nucleic acid sequences will not be published without an accession number to GenBank/EMBL/DDBJ, SWISS-PROT, or another appropriate database in the field that provides free access to the data for all scientists from the date of publication.

**Crystal and NMR Structures.** Small molecular crystallographic data should be submitted upon publication to the Cambridge Structural Database ([www.ccdc.cam.ac.uk](http://www.ccdc.cam.ac.uk)). Papers reporting macromolecular NMR or crystal structures must specifically state that the atomic coordinates have been deposited in the Protein Data Bank (PDB) ([www.rcsb.org/pdb/home/home.do](http://www.rcsb.org/pdb/home/home.do)) or the Nucleic Acid Database (<http://ndbserver.rutgers.edu>) and must list the accession code(s). These coordinates must be designated “for immediate release upon publication”. Authors of papers reporting X-ray crystal structures are encouraged to deposit the structure factor files in the PDB. No formal

requirement exists for deposition of NMR assignments and constraints (see Biological Magnetic Resonance Data Bank at [www.bmrb.wisc.edu](http://www.bmrb.wisc.edu)).

*Electron Microscopy Data.* No formal requirement exists for deposition of molecular envelope reconstruction from electron microscopy data, but the journal encourages authors to deposit relevant information in appropriate databases. Approved databases for deposition of electron microscopy data are the Worldwide Protein Data Bank ([www.wwpdb.org](http://www.wwpdb.org)), the Protein Data Bank Japan ([pdbj.org/](http://pdbj.org/)), or the Protein Data Bank in Europe (PDBe) ([www.ebi.ac.uk/pdbe/](http://www.ebi.ac.uk/pdbe/)).

*Microarray Data.* Data must be submitted to the GEO ([www.ncbi.nlm.nih.gov/geo](http://www.ncbi.nlm.nih.gov/geo)) or ArrayExpress ([www.ebi.ac.uk/arrayexpress](http://www.ebi.ac.uk/arrayexpress)) databases and the relevant accession numbers included in the published manuscript. Please reference the Microarray Gene Expression Data (MGED) open letter specifying microarray standards at [http://www.mged.org/Workgroups/MIAME/miame\\_checklist.html](http://www.mged.org/Workgroups/MIAME/miame_checklist.html).

*Genetically Modified Organisms and Mutants.* Use established repositories such as the Jackson Laboratory, the Mutant Mouse Regional Resource Center, the American Type Culture Collection, the UK Stem Cell Bank, or another public storage area whenever possible. Large datasets for which an approved database has not yet been established must be housed as online Supporting Information on the journal's website.

***Material and Data Availability.*** *ACS Infectious Diseases* understands that communication and collaboration between chemists and biologists are significantly enhanced when materials and data can be exchanged among scientists. Therefore, a condition of publication is that authors are required to make materials, data, and protocols available to readers through deposition in a publicly used database. Hosting on an author's website is not an acceptable substitute. Authors also agree to make available to interested academic researchers for their own use any materials reported in their manuscript that are not otherwise obtainable. Any restrictions to the availability of materials or information must be stated at the time of submission.

***Online Publication, Publication Dates, and Patent/IP Considerations.*** *Just Accepted Manuscripts.* Just Accepted Manuscripts are peer-reviewed, accepted manuscripts that are posted on the ACS Publications website prior to technical editing, formatting for publication, and author proofing—usually within 30 minutes to 24 hours of acceptance by the editorial office. During the manuscript submission process, authors can choose to have their manuscript posted online as a *Just Accepted* manuscript. All authors can select the *Just Accepted* service. However, Authors are responsible for ensuring that all intellectual property issues are resolved prior to manuscript acceptance. Because the process is completely automated, it is critical that the accepted version of the manuscript is complete and prepared according to the requirements in these author instructions and all intellectual property issues are resolved prior to acceptance. The cover page for the Just Accepted posting is generated from the entries in the Paragon Plus database, so it is imperative that the author names in that database match exactly the author names on the title page in content and order. Once the manuscript is posted on the web, it is accessible to all readers, and is indexed by SciFinder, PubMed and Google. For further information, please refer to the *Just Accepted* FAQ, at <http://services.acs.org/pubshelp/passthru.cgi?action=kb&item=244>. Note that publishing a manuscript as Just Accepted is not a means by which to comply with the NIH Public Access Mandate.

When page proofs are made available, authors should review the proofs in detail to ensure that the text and figures are correct. *ACS Infectious Diseases* will publish manuscripts As Soon As Publishable (ASAP) online when proofs are corrected and all author concerns are resolved, usually within days after the authors return their corrected proofs. These ASAP articles represent the final, published scientific articles of record. The Just Accepted posting will be deleted when the ASAP posting is made. As with *Just Accepted* manuscripts, authors should take this schedule into account when planning intellectual and patent activities related to a manuscript.

The actual date on which an accepted paper is published on the web is recorded on the HTML version of the manuscript and on the first page of the PDF version. Published manuscripts are definitive and may be altered only through an Addendum or Erratum. All published papers receive a unique digital object identifier (DOI) number ([www.doi.org/](http://www.doi.org/)), which may be used to cite the paper at all stages of its existence.

**Security Concerns.** Certain manuscripts may represent a potential security risk for the public. Such manuscripts will be brought to the attention of Editors of the journal. If necessary, outside reviewers with expertise in security matters will be consulted.

## **Submission Procedure**

Authors must submit manuscripts online at <http://paragonplus.acs.org/login>. Complete details regarding acceptable file formats, etc., are available at this site. Submission is taken to imply that all co-authors have approved of the content and submission to *ACS Infectious Diseases* and that the corresponding author is authorized to represent all authors. The web submission site employs state-of-the-art security mechanisms to ensure that all electronically submitted manuscripts are secure. These same security mechanisms are also utilized throughout the peer-review process, permitting access only to Editors and reviewers who are assigned to a particular paper.

**ORCID.** Authors submitting manuscript revisions are required to provide their own personal, validated ORCID iD before completing the submission, if an ORCID iD is not already associated with their ACS Paragon Plus user profiles. This iD may be provided during original manuscript submission or when submitting the manuscript revision. All authors are strongly encouraged to register for an ORCID iD, a unique researcher identifier. The ORCID iD will be displayed in the published article for any author on a manuscript who has a validated ORCID iD associated with ACS when the manuscript is accepted.

With an ORCID iD, you can create a profile of your research activities to distinguish yourself from other researchers with similar names, and make it easier for your colleagues to find your publications. If you do not yet have an ORCID iD, or wish to associate your existing ORCID iD with your ACS Paragon Plus account, you may do so by following the ORCID-related links in the Email/Name section of your [ACS Paragon Plus](#) account. Learn more at <http://www.orcid.org>.

**Cover Letter.** A letter must accompany the submission, and it must contain the following elements:

- Manuscript title
- Name of the corresponding author
- Name(s) of any other author(s)

- A paragraph explaining why the paper is appropriate for *ACS Infectious Diseases*, and
- Note whether the manuscript was discussed with an *ACS Infectious Diseases* Editor before submission
- A short (~150 word) lay summary (at the level of an undergraduate in biochemistry) describing the significance of the study for a broad audience

If your manuscript is accepted for publication, *ACS Infectious Diseases* may choose to modify, edit, and publish a brief account of your current position, education, nonscientific interests, and research interests in the *Introducing Our Authors* feature of the journal. The journal may also promote your research article through press communications.

**Manuscript Transfer Service.** If your submission is declined for publication by this journal, the Editors might deem your work to be better suited for another ACS Publications journal and suggest that the authors consider transferring the submission. The Manuscript Transfer Service simplifies and shortens the process of submitting to another ACS journal, as all the coauthors, suggested reviewers, manuscript files, and responses to submission questions are copied by ACS Paragon Plus to the new draft submission. Authors are free to accept or decline the transfer offer.

Once a transfer is accepted, authors will then complete the submission to the new journal in ACS Paragon Plus. During the submission process, they will have the opportunity to revise the manuscript and address comments received from Editors or reviewers. Requirements of the new journal may be different, so authors should also check the Author Guidelines for the new journal and make any needed revisions in order to conform to those requirements. Please keep in mind that the reviews, reviewer identities, and decision letter will all be transferred to the new journal. Authors are encouraged to identify changes made to the manuscript in a cover letter for the new journal.

Note that transferring a manuscript is not a guarantee that the manuscript will be accepted, as the final publication decision will belong to the Editor in the new journal. For complete details, see [http://pubs.acs.org/page/policy/manuscript\\_transfer/index.html](http://pubs.acs.org/page/policy/manuscript_transfer/index.html).

**Journal Publishing Agreement.** A properly completed and signed Journal Publishing Agreement must be submitted for each manuscript. ACS Paragon Plus provides an electronic version of the Agreement that will be available on the **My Authoring Activity** tab of the corresponding author's home page once the manuscript has been assigned to an Editor. A PDF version of the Agreement is also available, but **authors are strongly encouraged to use the electronic Journal Publishing Agreement.** If the PDF version is used, **all pages of the signed PDF Agreement must be submitted.** If the corresponding author cannot or should not complete either the electronic or PDF version for any reason, another author should complete and sign the PDF version of the form. Forms and complete instructions are available at <http://pubs.acs.org/page/copyright/journals/index.html>.

**Funding Sources.** Authors are required to report ALL funding sources and grant/award numbers relevant to the manuscript. Enter all sources of funding for ALL authors relevant to the manuscript BOTH in the Open Funder Registry tool in ACS Paragon Plus and in the manuscript to meet this requirement. See [http://pubs.acs.org/page/4authors/funder\\_options.html](http://pubs.acs.org/page/4authors/funder_options.html) for complete instructions.

## Additional Requirements

**Nomenclature.** Use abbreviations and acronyms sparingly, and all usage should be defined at the first occurrence in the text. Whenever possible, use systematic nomenclature as recommended by IUPAC and IUBMB for chemical compounds and biomolecules. Names of organisms should comply with genetic conventions, with genus and species names written in italics and spelled out in full on first appearance. Gene symbols should conform to approved nomenclature and should be italicized, whereas corresponding protein products should start with a capital letter and should not be italicized. Consult the available nomenclature databases (e.g., Entrez Gene, [www.ncbi.nlm.nih.gov/gene/](http://www.ncbi.nlm.nih.gov/gene/)) for correct names and symbols. Enzyme names should be accompanied by their Enzyme Commission numbers.

**Chemical Compound Characterization.** Knowledge of the purity of compounds employed in biological studies, whether they are synthesized, purchased, or received as gifts, is a crucial factor for obtaining reliable and reproducible results. For studies reported in *ACS Infectious Diseases*, it is recommended that assayed compounds be at least 90% pure as judged by HPLC, LC-MS, and NMR. The analytical methods used for compound characterization and purity assessment should be mentioned in the Methods section. For novel compounds, it is important to obtain such data to confirm their structure and purity. Manuscripts for *ACS Infectious Diseases* should *at least* provide exemplary characterization data for key compounds, including LC-MS, HPLC, <sup>1</sup>H NMR/<sup>13</sup>C NMR (peak lists), and HRMS. For compounds prepared in a library format, a general experimental procedure should be provided, including full experimental details, with yields, for a representative selection of library members. The synthesis protocols and selected characterized compounds must reflect the reliability and scope of the reaction sequence. The purity of all reported library compounds should be explicitly stated. The submission of manuscripts purely based on mixture synthesis and/or mixture analysis is discouraged.

**Use of Human Subjects or Animals in Research.** The American Chemical Society Publications rules and ethical guidelines provide mandatory standards of practice in experimental studies performed using biological samples obtained from animals or human subjects. Studies submitted for publication approval must present evidence that the described experimental activities have undergone local institutional review assessing safety and humane usage of study subject animals. In the case of human subjects authors must also provide a statement that study samples were obtained through the informed consent of the donors, or in lieu of that evidence, by the authority of the institutional board that licensed the use of such material. Authors are requested to declare the identification or case number of institution approval as well as the name of the licensing institution.

## Conditions of Acceptance

When a paper is accepted for publication in *ACS Infectious Diseases*, the authors:

- Will honor any reasonable request from Editors, reviewers, and other scientists for materials, methods, or data necessary for verification of the conclusions reported in the paper;

- Will have deposited protein and nucleic acid sequences, crystallographic structures, and microarray data in approved databases and provided accession numbers for inclusion in the published manuscript as described in the deposition policies described above;
- Will provide assurance that animals used in the study were cared for in accordance with institutional guidelines;
- Will verify that, in human studies, consent was obtained after the consequences of the studies had been explained to the experimental subjects (all research on humans must have IRB approval);
- Agree to disclose all potential sources of bias, including affiliations, funding sources, and financial or management relationships, that may constitute conflicts of interest; and
- Will not release to the press or the public the accepted manuscript prior to the stated embargo date.

## ***Additional Journal Information***

***ACS AuthorChoice Open Access.*** [ACS AuthorChoice](#) options establish fee-based mechanisms for authors or their research funding agencies to sponsor the open availability of final published articles on the web. *ACS AuthorChoice* offers authors a wide range of open access license options, such as Creative Commons licenses and provisions for immediate or 12-month embargoed open access, and includes [ACS Certified Deposit](#). Authors will find useful information about compliance with open access policies available [here](#) and FAQs [here](#). Corresponding authors who published with ACS during 2014 may have access to [ACS Author Rewards](#), a \$60M stimulus program ACS provided to help authors transition to new open access publishing models.

Authors must sign the Journals Publishing Agreement. Forms and complete instructions are available [here](#). After acceptance, authors will be presented with the opportunity to purchase an *ACS AuthorChoice* option, and authors who do so will be presented with the appropriate license at that time. For a review of all license options available, see [here](#). For questions or further assistance with *ACS AuthorChoice*, please reach out to [support@services.acs.org](mailto:support@services.acs.org).

***The ACS AuthorChoice Option.*** The *ACS AuthorChoice* option establishes a fee-based mechanism for authors or their research funding agencies to sponsor the open availability of their articles on the web at the time of online publication. Effective January 1, 2014, *ACS AuthorChoice* will be expanded to offer authors a wider range of open access license options, such as Creative Commons licenses and provisions for immediate or 12-month embargoed open access, both coupled with a new *ACS Certified Deposit* service. For complete details see <http://acsopenaccess.org/>.

ACS offers three options by which authors can fulfill the requirement of manuscript deposit for NIH funded research. For further information, please refer to the following website: <http://pubs.acs.org/page/policy/nih/index.html>.

***Sharing Manuscripts.*** Under the *ACS Articles on Request* policy, the Society will provide (free of charge) to all contributing authors a unique URL within the ACS website that they may e-mail to colleagues or post on external websites. These author-directed links are designed to facilitate distribution of an author's published work to interested colleagues in lieu of direct distribution of the

PDF file by the author. The ACS Articles on Request policy allows 50 downloads within the first year after web publication and unlimited access via the same author-directed links 12 months after web publication. For additional details, please refer to the following link: <http://pubs.acs.org/page/policy/articlesonrequest/index.html>

**Proofs.** Correction of the galley proofs is the responsibility of the corresponding (submitting) author. Authors will receive a link to their proofs via e-mail. Authors will access the secure site through ACS ChemWorx and will need an ACS ID. To obtain an ACS ID or to reset your password, go to [www.acschemworx.org](http://www.acschemworx.org). Corrections are limited to errors; authors are not permitted to rewrite sections at this stage of production. Substantive changes will require the approval of the Editor. It is the responsibility of the corresponding author to ensure that all authors listed on the manuscript agree with the changes made on the proofs. Corrections should be submitted according to the instructions on the author galley website. ***Galley proofs should be returned in <48 hours of receipt to ensure timely publication of the manuscript.*** Corrected articles will be posted on the *ACS Infectious Diseases* ASAP website within a few days of receipt of the galley proofs.

**Reprints.** *Hardcopy reprints must be ordered when the galley proof is received.* A reprint order form, showing the cost of reprints, is included with the galley proof. Please review the ordering instructions and return the reprint order form with purchase order or payment. Reprints will be shipped within ~2 weeks of the published issue date.